AKR1B10 also catalyzes reduction in the carbonyl groups of daunomycin and idarubicin, drugs used in the treatment of AML, in the cytoplasm, converting the drugs into water-soluble inactive alcohols. Here, AKR1B10 is linked to acute myeloid leukemia.